Search clinical trials for: Coagulation factor

Total 38391 results

Hospices Civils de Lyon

Unknown

TGA (Thrombin Generation Assay) and Prophylaxis in Haemophilia (HOPE)

Haemophilia A

France
Novo Nordisk A/S

Completed

Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study (mentor™6)

Congenital Bleeding Disorder | Congenital FXIII Deficiency

Spain, United States, Canada, Italy, United Kingdom, Hungary
Margaret Ragni
Wyeth is now a wholly owned subsidiary of Pfizer; University of North Carolina

Terminated

IL-11 in Adults With Von Willebrand Disease Undergoing Surgery

Von Willebrand Disease

United States
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral FIX Gene Therapy

Hemophilia B
Shenzhen Geno-Immune Medical Institute

Unknown

Lentiviral FVIII Gene Therapy

Hemophilia A

China
Pfizer

Terminated

Understanding Hemophilia A and B Drug Dosage Administration Patterns

Hemophilia A | Hemophilia B

United States
Centre Hospitalier Universitaire Dijon

Unknown

Mutation p.Ile112Thr : Discrepancy Between Factor IX Level and Bleeding Phenotype (Hémophilie B)

Hemophilia B

France
Ronald Hoffman
National Cancer Institute (NCI); Roche Pharma AG; Myeloproliferative Disorders-Research...

Completed

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

High Risk Polycythemia Vera | High Risk Essential Thrombocythemia

United States, Italy, United Kingdom, France
Pfizer

Completed

Post-Marketing Surveillance To Observe Safety And Efficacy Of Xyntha Solofuse Prefilled Syringe

Factor VIII Deficiency, Congenital | Hemophilia A, Congenital | Factor 8 Deficiency, Congenital | Autosomal Hemophilia A | Classic Hemophilia
Bayer

Completed

Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment (ECHO)

Hemophilia A

United States, Japan, United Kingdom, Spain
Spark Therapeutics
Children's Hospital of Philadelphia; University of Pittsburgh; St. James's Hospital... and other collaborators

Terminated

Hemophilia B Gene Therapy With AAV8 Vector

Hemophilia B

United States, Australia
Cairo University

Completed

Prediction of Outcome in Severe Preeclampsia

Leiden Factor V Deficiency,Preeclampsia | Doppler Examination | Palental Pathology
Liaoning University of Traditional Chinese Medicine
Shengjing Hospital; First Hospital of China Medical University

Unknown

Cohort Study on Traditional Chinese Medicine Diagnosis and Treatment of Children With Henoch-Schonlein Purpura Nephritis (CSTCMDTCHSPN)

Henoch-Schonlein Purpura Nephritis

China
Bio Products Laboratory

Terminated

Safety & Efficacy of BPL's High Purity FACTOR X in Treatment of Factor X Deficient Subjects Undergoing Surgery (Ten03)

Factor X Deficiency

United Kingdom, United States, Spain, Turkey
Lund University
Shire

Completed

Evaluation of a Standardized Protocol for Thrombin Generation Assay

Hemophilia A

Sweden
Pfizer

Completed

Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII

Hemophilia A

United States, Argentina, Austria, Colombia, Croatia, Jordan, Mexico, New Zealand, Oman, Peru, Poland, Romania, Turkey
Weill Medical College of Cornell University
Genentech, Inc.; Biogen

Completed

Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP

Immune Thrombocytopenic Purpura

United States
Lund University

Withdrawn

Key Aspects of Medical Practice in Patients With Haemophilia A (KAPPA)

Joint Disease
Hospital Israelita Albert Einstein

Completed

Viscoelastic Tests-Guided Therapy In Liver Transplantation (VETLT)

Bleeding | Liver Transplant; Complications | Hemostatic Disorder
University Hospital Goettingen

Completed

Evaluation of Coagulation Factors and Point-of-care Devices During Veno-venous ECMO Therapy

Extracorporeal Membrane Oxygenation Complication | Coagulation Factor Deficiency

Germany
Peking Union Medical College Hospital

Unknown

Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A

Acquired Hemophilia A

China
Children's Hospital of Orange County
CSL Behring

Completed

Clinical Trial of Factor XIII (FXIII) Concentrate

Hemophilia | Factor XIII Deficiency

United States
University Hospital Inselspital, Berne
Schweizerische Herzstiftung

Completed

The Role of Factor XIII Activation Peptide and D-dimer Values for the Diagnosis of Cerebral Venous Thrombosis (CVT)

Cerebral Venous Thrombosis

Switzerland, Netherlands
Bayer

Completed

Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies (PARkER)

Hemophilia A

United States
University College, London

Unknown

TTP and aHUS in Complicated Pregnancies

Thrombotic Microangiopathies | Thrombotic Thrombocytopenic Purpura | Thrombocytopenia | Pre-Eclampsia | HELLP Syndrome | Stillbirth | Atypical Hemolytic Uremic Syndrome | IUGR

United Kingdom
Pfizer

Completed

Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO

Hemophilia A

Italy
Wyeth is now a wholly owned subsidiary of Pfizer

Withdrawn

Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A

Hemophilia A

Italy, United States, Netherlands, United Kingdom, Germany, New Zealand, Belgium, France
Bayer

Completed

Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

Hemophilia A

United States
Novo Nordisk A/S

Completed

Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

France, United States, Sweden, Serbia, Turkey, United Kingdom, Malaysia, Brazil, Former Serbia and Montenegro, Japan, South Africa
Weill Medical College of Cornell University

Withdrawn

Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia

Immune Thrombocytopenia
Academisch Medisch Centrum - Universiteit van Amsterdam...

Unknown

The Dynamic Interplay Between Bleeding Phenotype and Baseline Factor Level in Moderate and Mild Hemophilia A and B (DYNAMO)

Hemophilia

Netherlands, Austria, Australia, Belgium, Canada, Finland, Germany, Italy, Spain, United Kingdom
Laboratoire français de Fractionnement et de Biotechnologies

Completed

Willebrand International Non-interventional Global Surveillance

Von Willebrand Disease

Norway, Germany, Italy, Belgium, Czechia, Finland, Greece
Beijing Children's Hospital

Unknown

Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China (HA-LD-ITI)

Hemophilia A With Inhibitor

China
Pfizer

Completed

Study Evaluating Pharmacovigilance Of Refacto AF

Hemophilia A

Germany, Austria
Weill Medical College of Cornell University
Genentech, Inc.

Withdrawn

A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone

Idiopathic Thrombocytopenic Purpura (ITP)

United States
Emory University

Completed

Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers

Hemophilia A

United States
Assiut University

Completed

Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia

Immune Thrombocytopenia

Egypt
Samsung Medical Center

Unknown

Edoxaban for the Treatment of Coagulopathy in Patients With Active Cancer and Acute Ischemic Stroke: a Pilot Study. (ENCHASE Study) (ENCHASE)

Correction of Cancer-related Coagulopathy With Novel Oral Anticoagulant (Edoxaban)

Korea, Republic of
University Hospital, Rouen

Unknown

Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study) (CREHA)

Acquired Haemophilia

France
National Cancer Institute (NCI)

Completed

Genetic Susceptibility to Factor VIII Inhibitors

Hemophilia

Sweden
Bio Products Laboratory

Completed

A Study to Investigate Bio Product Laboratory Ltd (BPL's) Factor X in the Prophylaxis of Bleeding in Children <12 Years

Factor X Deficiency

United Kingdom
Shandong University
The Affiliated Hospital of Qingdao University; Yantai Yuhuangding Hospital

Unknown

Rituximab Combining Bortezomib Versus Rituximab in Management of ITP

Purpura, Thrombocytopenic, Idiopathic | Immune Thrombocytopenia

China
Hampshire Hospitals NHS Foundation Trust
Uppsala University; University of Wales Cardiff United Kingdom (UK)

Completed

Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A

Severe Haemophilia A

United Kingdom
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients

Haemophilia B

United Kingdom, Poland
Bio Products Laboratory

Completed

An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery

Haemophilia B

Poland, Romania, Russian Federation
Bio Products Laboratory

Completed

A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Surgery.

Haemophilia B

United Kingdom
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery.

Haemophilia A

Poland, United Kingdom
Bio Products Laboratory

Completed

A Study to Compare the Pharmacokinetics and Safety of Optivate® and Haemate P® in Patients With Von Willebrand Disease.

vonWillebrand's Disease

Israel
Bio Products Laboratory

Completed

An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.

Haemophilia A

United Kingdom, Poland
Bio Products Laboratory

Completed

A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.

Von Willebrand Disease

Poland, United Kingdom

Search clinical trials for: Coagulation factor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Costa Rica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations